Safety of biweekly alpha1 antitrypsin treatment in the RAPID program

Alpha-1 antitrypsin deficiency (AATD) is a hereditary disorder characterised by an abnormally low concentration of functional alpha-1 antitrypsin (AAT) in blood and tissues [1]. The primary role of AAT is to protect elastin-containing tissues, most notably the lung, against the destructive activity of proteolytic enzymes [2]. Patients with severe AATD present with serum AAT concentrations below 11 µM and are prone to destruction of the lung tissue, often developing respiratory symptoms and emphysema in the fourth or fifth decade of life [3, 4].Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Greulich reports personal fees from AstraZeneca, personal fees from Boehringer-Ingelheim, personal fees from Chiesi, personal fees from CSL-Behring, grants and personal fees from Grifols, personal fees from GSK, personal fees from Mundipharma, personal fees from Novartis, outside the submitted work.Conflict of interest: Dr. Chlumsky reports personal fees from honoraria for lectures organized by CSL Behring, personal fees from honoraria for lectures organized by Boehringer Ingelheim, outside the submitted work.Conflict of interest: Dr. Wencker is a consultant to CSL Behring.Conflict of interest: Mr. Vit reports no other conflicts of interest outside of his employment with CSL Behring during the conduct of the study.Conflict of interest: Dr. Fries reports no other conflicts of interest outside of his employment with CSL Behring during the conduct of the study.Conflict of interest: Dr. Chung reports no other conflicts of interest outside of his employment with CSL Behring during the conduct of the study.Conflict of interest: Dr. Shebl reports no other conflicts of interest outside of his employment with CSL Behring during the conduct of the study.Conflict of interest: Dr. Vogelmeier reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from CSL Behring, personal fees from Chiesi, grants and personal fees from GlaxoSmithKline, grants and personal fees from Grifols, personal fees from Menarini, personal fees from Mundipharma, grants and personal fees from Novartis, personal fees from Teva, personal fees from Cipla, grants from Bayer-Schering, grants from MSD, grants from Pfizer, outside the submitted work.Conflict of interest: Dr. Chapman reports grants and personal fees from AstraZeneca, grants and personal fees from BoehringerIngelheim, grants from Baxter, grants and personal fees from CSL Behring, grants and personal fees from Grifols, grants from GlaxoSmithKline, grants and personal fees from Sanofi, grants and personal fees from Genentech, grants and personal fees from Kamada, grants from Amgen, grants and personal fees from Roche, grants and personal fees from Novartis, personal fees from Merck, personal fees from CIHR-GSK Research Chair in Respiratory Health Care Delivery, UHN, grants from Shire, grants from Octapharma, during the conduct of the study.Conflict of interest: Dr. McElvaney reports grants from CSL Behring, during the conduct of the study; personal fees from CSL behring, outside the submitted work.